Ebolaviruses belongs to the family of Filoviridae in the order of Mononegavirales. The genome is a single, negative polarity strand of RNA. EBOV is one of the most virulent pathogens among viral haemorrhagic fevers, with case fatality rates of up to 90% reported. Mortality is the result of multi-organ failure and serious bleeding complications. By 18 September 2014, the WHO reported 5,335 cases (confirmed, suspected and probable) with 2,622 deaths, resulting in a case fatality rate of around 50%. There are no approved medications or vaccines available for EVD until today; supporting care is the pillar of therapy. There are, however, a number of therapeutic approaches along the way that could have a real impact on the control and prevention of this global threat. This review aims to provide clinicians with an overview of EVD with emphasis on epidemiology, clinical manifestations and options for treatment.
Cite this article:
Akshay R. Yadav, Shrinivas K. Mohite. An Overview on Ebola Virus Disease. Res. J. Pharma. Dosage Forms and Tech.2020; 12(4):267-270. doi: 10.5958/0975-4377.2020.00044.0
1. Karunakar T, Kumar E, Naresh K, Sriram R. A review on Ebola virus. Int J Pharmacother. 2013;3(2): 55-59.
2. Johnson KM, Lange JV, Webb PA, Murphy FA. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet. 1977;1: 569-71.
3. Le GB, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 1995;345: 1271-1274.
4. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Sci. 2014;345: 1369-1372.
5. Bausch DG, Bangura J, Garry RF, et al. A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: Mae we hush. Antiviral Res. 2014;111C:33-35.
6. Hartman AL, Towner JS, Nichol ST. Ebola and Marburg hemorrhagic fever. Clin Lab Med. 2010;30: 161-177.
7. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210: 558-566.
8. Baize S, Pannetier D, Oestereich L. Emergence of Zaire Ebola Virus Disease in Guinea – Preliminary Report. N Engl J Med. 2014;371: 1418-1425.
9. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17: 964-976.
10. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77: 7539-7544.
11. Van Gorp EC, Setiati TE, Mairuhu AT. Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever. J Med Virol. 2002;67: 549-554.
12. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis. 1999;179: 224-234.
13. Warren TK, Wells J, Panchal RG. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508: 402-405.
14. Leirs H, Mills JN, Krebs JW, et al. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis. 1999;179: 155-163.
15. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, Sow A, Renne T, Gunther S, Lohse AW. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371(25):2394–2401.
16. Connor MJ Jr, Kraft C, Mehta AK, Varkey JB, Lyon GM, Crozier I, Stroher U, Ribner BS, Franch HA. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol. 2015;26(1): 31–37.
17. Gignoux E, Azman AS, de Smet M, Azuma P, Massaquoi M, Job D, Tiffany A, Petrucci R, Sterk E, Potet J. Effect of Artesunate-Amodiaquine on mortality related to Ebola virus disease. N Engl J Med. 2016; 374(1): 23–32.
18. Dufour-Gaume F, Delaune D, Martinaud C, Sailliol A. Early and repeated use of plasma for the management of Ebola patients: reflection around a case. Transfus Clin Biol. 2017;24(1):5–8.
19. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013;8(4):605-609.
20. Liu G, WongG, Su S, BiY, Plummer F, GaoGF, KobingerG, Qiu X. Clinical evaluation ofEbola virusdisease therapeutics. Trends Mol Med. 2017;23(9):820-830.